<DOC>
	<DOCNO>NCT00961194</DOCNO>
	<brief_summary>Nowadays , available drug always produce pain relief patient neuropathic pain disease . It believe drug act antagonist N-methyl-D-aspartic acid ( NMDA ) receptor may efficient treatment neuropathic pain disorder . Ketamine NMDA receptor antagonist commercially available France . Ketamine usually administer intravenously surgical anesthesia . The intravenous administration ketamine difficult manage treatment chronic neuropathic pain . Some trial use oral ketamine treatment neuropathic pain conduct result heterogeneous . This may explain different range ketamine dos test . The aim clinical trial identify safe efficient dose orally administrated ketamine treatment peripheral neuropathic pain . The clinical trial conduct Toulouse Hospital , France . This study randomize , double-blind , placebo-controlled trial . The study conduct use 4 parallel group ( three dos ketamine versus placebo ) .</brief_summary>
	<brief_title>Oral Ketamine Administration Patients With Peripheral Neuropathic Pain</brief_title>
	<detailed_description>In previous study , show ketamine administrate intravenous route , analgesic action rapid . In one study , oral ketamine administrate patient suffer neuropathic pain , six nine patient , pain relieve 24 hour post-administration . In study , ketamine administrate seven day , allow u evaluate ketamine efficiency safety . The effect ketamine pain intensity mainly study use visual analogue scale ( VAS ) also take account score assign patient pain . This score note patient , ketamine treatment . Evaluation benefit/risk ketamine administration trial , show even adverse event exclude , benefit patient may neuropathic pain relief . Because clinical current knowledge regard oral administration ketamine limit , trial intend enlarge information ketamine efficiency safety , particularly neuropathic pain disorder .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Patients must suffer peripheral neuropathic chronic pain . Pain score must least 40 mm VAS ( reflect pain intensity 7 day day visit 1 ) . Patients pain satisfactory relieve level 1 , 2 3 analgesic drug ( associate antidepressant antiepileptic drug ) . Patients treat level 2 3 analgesic drug must stop treatment one week ketamine treatment . Patients must benefit French Social security system . Patients must able complete test . Patients must give write informed consent . Patients must age 30 90 year . Female fertile patient must use efficient method contraception . Patients suffer peripheral neuropathic chronic pain . Pain score less 40 mm VAS ( reflect pain intensity 7 day day visit 1 ) . Patients able complete test . Patients able stop level 2 3 analgesic drug . Patients ketamine contraindicate : Hypersensibility one compound ketamine syrup Uncontrolled arterial hypertension Recent cardio vascular accident Severe cardiac problem Drug abuse Psychosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>pain</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>chronic</keyword>
</DOC>